Scarica il documento in formato pdf (1196 KB) - ANCE

Giornale Italiano di Cardiologia Pratica - It J Practice Cardiol Dicembre 2007-Marzo 2008
misura proprio a causa di danni jatrogenici, in larga
misura favoriti o indotti dalla stessa terapia antiretrovirale
[12, 13, 39-41, 74], ed al progressivo incremento dell’età
media della popolazione dei soggetti HIV-positivi,
che si registra da anni nei Paesi industrializzati [2, 3].
BIBLIOGRAFIA
1. Manfredi R. Dismetabolismo e rischio di eventi avversi cardio-cerebrovascolari
in pazienti con infezione da HIV trattati
con terapia antiretrovirale. Giornale Italiano di Cardiologia
Pratica 2007; 5 (2-3): 65-75
2. Manfredi R. HIV disease and advanced age: an increasing
therapeutic challenge. Drugs Aging 2002; 19:647-69
3. Manfredi R. HIV infection and advanced age: emerging epidemiological,
clinical, and management issues. Ageing Res
Rev 2004; 3:31-54
4. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E.
Hypofibrinolytic state in HIV-1-infected patients treated with
protease inhibitor-containing highly active antiretroviral
therapy. J Acquir Immune Defic Syndr 2002; 29:441-9
5. De Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R.
HIV infection, HAART, and endothelial adhesion molecules:
current perspectives. Lancet Infect Dis 2004; 4:213-22.
6. Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive
patients. AIDS 2005 19:641-52
7. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with
antiretroviral therapy in HIV-infected patients. J Antimicrob
Chemother 2004; 53:10-4
8. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients
with HIV-1 infection receiving highly active antiretroviral
therapy: epidemiology, pathogenesis, clinical course and
management. Int J Antimicrob Agents 2003; 22:89-99.
9. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation
and management of dyslipidemia in human immunodeficiency
virus (HIV)-infected adults receiving antiretroviral
therapy: recommendations of the HIV Medicine
Association of the Infectious Disease Society of America and
the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;
37:613-27
10. Expert Panel on Detection, Evaluation and Treatment of
High Blood Cholesterol in Adults. Executive summary of the
third report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation and
Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III). JAMA 2001; 285:2486-97
11. Manfredi R. High-risk dysmetabolism disorders associated
with HAART-treated HIV disease, and reimbursement of
lipid-lowering drugs, in a clinical and a socio-economic perspective.
AIDS Rev 2005; 7:155-60
12. Manfredi R. Farmaci ipolipidemizzanti e regime di rimborsabilità.
Nessuna considerazione clinico-preventiva,
socio-economica, ed etica per le iperlipidemie jatrogeniche
indotte dai farmaci antiretrovirali nei soggetti con infezione
da HIV. Journal of Medicine and the Person 2006; 4:189-90
13. Manfredi R, Calza L, Chiodo F. Gabexate mesilate and/or
octreotide in human immunodeficiency virus-associated
pancreatic abnormalities. Aliment Pharmacol Ther 2002;
16:1791-4
14. Manfredi R, Calza L, Chiodo. A case-control study of HIVassociated
pancreatic abnormalities during HAART era.
Focus on emerging risk factors and specific management.
Eur J Med Res 2004; 9:537-44
15. Stein JH. Managing cardiovascular risk in patients with HIV
infection. J Acquir Immune Defic Syndr 2005; 38:115-23
70
16. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol
Education Program Adult Treatment Panel III update: adjustments
and options. Am J Cardiol 2005; 96 (Suppl. 4A):53E-
9E
17. Manfredi R, Calza L, Chiodo F. Polyunsaturated ethyl esters
of n-3 fatty acids in HIV-infected patients with moderate
hypertriglyceridemia: comparison with dietary and lifestyle
changes, and fibrate therapy. J Acquir Immune Defic Syndr
2004; 36:878-80
18. Manfredi R. Need to evaluate the cost effectiveness of early
diagnosis and treatment of osteopenia and osteoporosis in
the setting of HIV and highly active antiretroviral therapy.
AIDS Patient Care STDs 2006; 20:665-7
19. Jones SP, Doran DA, Leatt PB, Maher B, Pirmohamed M.
Short-term exercise training improves body composition
and hyperlipidaemia in HIV-positive individuals with lipodystrophy.
AIDS 2001; 15:2049-51
20. Yarasheki KE, Tebas P, Stanerson B, et al. Resistance exercise
training reduces hypertriglyceridemia in HIV-infected men
treated with antiviral therapy. J Appl Physiol 2001; 90:133-8
21. Martínez E, Arnaiz JA, Podzamcer D, et al. Substitution of
nevirapine, efavirenz, or abacavir for protease inhibitors in
patients with human immunodeficiency virus infection. N
Engl J Med 2003 349:1036-46
22. Bucher HC, Kofler A, Nuesch R, Young J, Battegay M,
Opravil M. Meta-analysis of randomized controlled trials of
simplified versus continued protease inhibitor-based antiretroviral
therapy in HIV-1-infected patients. AIDS 2003;
17:2451-9
23. John M, McKinnon EJ, James R, et al. Randomized controlled
48-week study of switching stavudine and/or protease
inhibitors to combivir/abacavir to prevent or reverse lipoatrophy
in HIV-infected patients. J Acquir Immune Defic Syndr
2003; 33:29-33
24. Keiser PH, Sension MG, Dejesus E, et al. Susbtituting abacavir
for hyperlipidaemia-associated protease inhibitors in
HAART regimens improves fasting lipid profiles, maintains
virologic suppression, and simplifies treatment. BMC Infect
Dis 2005; 5:2-5
25. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety
of tenofovir DF vs stavudine in combination therapy in
antiretroviral-naive patients: a 3-year randomized trial. JAMA
2004;292:191-201
26. Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia
associated with highly active antiretroviral therapy
(HAART) on cardiovascular risk and life expectancy. Am J
Cardiol 2005;95:586-91
27. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al.
Switching to atazanavir improves metabolic disorders in
antiretroviral-experienced patients with severe hyperlipidemia.
J Acquir Immune Defic Syndr 2005; 39:174-80
28. Manfredi R, Motta R, Patrono D, Calza L, Chiodo F, Boni P. A
prospective case-control survey of laboratory markers of
skeletal muscle damage during HIV disease and antiretroviral
therapy. AIDS 2002; 16:1969-71
29. Manfredi R, Motta R, Patrono D, Calza L, Chiodo F, Boni P.
Frequency, risk factors and features of hyperlactatemia in a
large number of patients undergoing antiretroviral therapy.
AIDS 2003; 17:2131-3
30. Calza L, Manfredi R, Chiodo F. Hyperlactatemia and lactic
acidosis in HIV-infected patients receiving antiretroviral therapy.
Clin Nutrition 2005; 24:5-15
31. De Gaetano Donati K, Rabagliati R, Tumbarello M, et al.
Increased soluble markers of endothelial dysfunction in HIVpositive
patients under highly active antiretroviral therapy.
AIDS 2003; 17:765-8
32. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the